Skip to main content
TipRanks
Go Ultimate75% OFF

ArriVent BioPharma, Inc. (AVBP) Drug Pipeline

100 Followers
Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Arr-002Ovarian Cancer, Endometrial Cancer, Platinum-Resistant Ovarian Cancer (Proc), Metastatic Ovarian Cancer, Metastatic Endometrial CancerPhase IRecruitingPhase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.Aug 05, 2026―
Firmonertinib, Egfr-Tki Inhibitor Based On Investigator's ChoiceNon-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Egfr P-Loop And Alpha C-Helix Compressing, Egfr Pacc, Egfr Uncommon MutationsPhase IIIRecruitingStudy to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon MutationsAug 15, 2025
Mrg007Colorectal Cancer, Pancreatic Cancer, Gastric Cancer, Locally Advanced Or Metastatic Solid TumorsPhase IRecruitingA Study of MRG007 (ARR-217) in Patients With Advanced Solid TumorsJun 26, 2025
FirmonertinibNsclc, Adjuvant TreatmentPhase IIIRecruitingA Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations, Following Complete Surgical Resection With or Without Adjuvant Chemotherapy(FIRMOST)May 20, 2025
Platinum-Based Chemotherapy, Furmonertinib 240 Mg Oral, Daily, Furmonertinib 160 Mg Oral, DailyAdvanced Non-small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer, Egfr Exon 20 MutationsPhase IIIActive Not RecruitingStudy to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)Oct 31, 2022―
FurmonertinibNon-Small Cell Lung Cancer (Nsclc), Advanced Non-small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer, Egfr Exon 20 Mutations, Her2 Exon 20 Mutations, Egfr Uncommon Mutations, Including G719x And S768iPhase IActive Not RecruitingStudy of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) MutationsApr 06, 2022―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does ArriVent BioPharma, Inc. (AVBP) have in its pipeline
ArriVent BioPharma, Inc. AVBP is currently developing the following drugs: Arr-002, Firmonertinib, Egfr-Tki Inhibitor Based On Investigator's Choice, Mrg007, Firmonertinib, Platinum-Based Chemotherapy, Furmonertinib 240 Mg Oral, Daily, Furmonertinib 160 Mg Oral, Daily, Furmonertinib. These drug candidates are in various stages of clinical development as the company works toward FDA approval.